CADL earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -10.26. Updated 2026-07-23.
Candel Therapeutics (CADL) Research Hub
Candel Therapeutics (CADL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.79 USD (-2.99%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.26, market cap 0.55B. This hub links to the full technical, earnings and options research available for CADL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.79 USD (-2.99%) |
| 52-week range | 7.7 USD – 13.95 USD |
| Trend regime | Range |
| 14-day RSI | 20.8 (Oversold) |
| Trailing P/E | -10.26 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CADL
Covered Call on CADL: how it works, illustrative setup around the real 7.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CADL: how it works, illustrative setup around the real 7.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CADL: how it works, illustrative setup around the real 7.79 USD price, max profit/loss, breakeven and when to use it. Educational.
CADL technical analysis: range, last 7.79 USD, RSI 20.8, 52w range 7.7 USD–13.95 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CADL in?
Candel Therapeutics (CADL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CADL in an uptrend or downtrend?
As of 2026-10-26, CADL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CADL's trailing P/E ratio?
CADL's trailing P/E is -10.26, with a market cap of 0.55B. See the earnings research page for full valuation detail.
When does CADL next report earnings?
CADL is next scheduled to report earnings on 2026-08-13.